# Minimally Invasive Pancreatoduodenectomy for Pancreatic Cancer: Current Perspectives and Future Directions

## TL;DR

Minimally invasive surgery for pancreatic cancer is as safe and effective as traditional surgery in expert centers, but more long-term data and standardization are needed.

## Contribution

This review evaluates the current evidence on minimally invasive pancreatoduodenectomy for pancreatic cancer, emphasizing the need for PDAC-specific trials and standardization.

## Key findings

- MIPD achieves comparable safety and oncologic outcomes to open surgery in expert centers.
- MIPD offers benefits like reduced blood loss and faster recovery, but long-term survival data for PDAC remain limited.
- Outcomes depend heavily on surgeon experience and institutional volume.

## Abstract

Minimally invasive pancreatoduodenectomy has emerged as a feasible option for pancreatic cancer in expert centers. Current evidence shows comparable safety and oncologic adequacy to open surgery in selected patients, while long-term PDAC-specific data and standardization remain needed.

Background: Minimally invasive pancreatoduodenectomy (MIPD) has evolved from an experimental technique to a feasible surgical option for pancreatic cancer in selected settings. However, its oncologic adequacy, safety, and generalizability remain debated, particularly given the biological aggressiveness of pancreatic ductal adenocarcinoma (PDAC) and the technical complexity of the procedure. Methods: This narrative review critically summarizes contemporary evidence regarding MIPD for pancreatic cancer, with particular attention to randomized controlled trials (RCTs), meta-analyses, and large observational studies. We distinguish findings derived from mixed periampullary tumor cohorts from those specific to PDAC and evaluate methodological limitations, learning-curve effects, and sources of heterogeneity across studies. Results: Recent RCTs and meta-analyses demonstrate that, when performed by experienced surgeons in high-volume centers, MIPD achieves perioperative outcomes comparable to open pancreatoduodenectomy, with advantages including reduced blood loss, shorter hospital stay, and faster functional recovery. Importantly, oncologic parameters such as R0 resection rates and lymph node yield appear equivalent between approaches, although robust long-term survival data from PDAC-specific RCTs remain lacking. Emerging evidence supports the feasibility of MIPD in complex clinical scenarios, including after neoadjuvant therapy, in frail or elderly patients, and in selected cases requiring vascular resection. Nonetheless, outcomes are strongly influenced by surgeon experience, institutional volume, and patient selection. Cost-effectiveness analyses and data from lower-volume centers remain limited. Conclusions: Current evidence supports MIPD as a viable alternative to open surgery for pancreatic cancer in carefully selected patients treated at specialized centers. However, claims of oncologic superiority are premature. Future research should focus on PDAC-specific randomized trials, standardized quality metrics, and strategies to mitigate learning-curve and resource-related barriers to broader implementation.